Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Launched by NOVARTIS PHARMACEUTICALS · Nov 21, 2022

Keywords

ClinConnect Summary

This clinical trial, called SIRIUS-SLE 2, is studying a new treatment called ianalumab for patients with systemic lupus erythematosus (SLE), a condition that can cause inflammation and damage in various parts of the body. The trial will compare ianalumab, given as a monthly injection, to a placebo (a treatment that looks like ianalumab but has no active ingredients) to see how effective and safe it is when used alongside standard treatments that patients are already receiving.

To be eligible for this trial, participants need to be at least 12 years old (or 18 in certain areas), have a confirmed diagnosis of SLE for at least six months, and show signs of active disease. They should also be receiving other medications for lupus, such as corticosteroids or anti-malarial drugs. Participants will be monitored regularly throughout the study, and they will be able to contribute to the understanding of how ianalumab can help manage their condition. It's important to know that certain health conditions or recent treatments may prevent someone from participating, so potential participants should discuss this with their doctor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female participants aged 12 years or older at the time of screening, or limited to 18 years or older in European Economic Area countries and other countries where inclusion of participants below 18 years is not allowed.
• • Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior to screening.
• • Elevated serum titers at screening of anti-nuclear antibodies ≥ 1:80 as determined by a central laboratory with a SLE-typical fluorescence pattern.
• • Currently receiving CS and/or anti-malarial treatment and/or another disease-modifying antirheumatic drug (DMARD) as specified in the protocol.
• • SLEDAI-2K criteria at screening: SLEDAI-2K score ≥ 6 points, excluding points attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome"
• * BILAG-2004 disease activity level at screening of at least 1 of the following:
• • BILAG-2004 level 'A' disease in ≥ 1 organ system, Or
• • BILAG-2004 level 'B' disease in ≥ 2 organ systems
• • Weigh at least 35 kg at screening
• Exclusion Criteria:
• • Prior treatment with ianalumab
• • History of receiving following treatment I) high dose CS, calcineurin inhibitors, JAK or other kinase inhibitors or other DMARD (except as listed in inclusion criteria) administered within 12 weeks prior to screening II) cyclophosphamide or biologics such as immunoglobulins (intravenous or s.c.), plasmapheresis, anti-type I interferon receptor biologic agents, anti-CD40 agents, CTLA4-Fc Ig or B-cell activating factor (BAFF)-targeting agents administered within 24 weeks prior to screening; belimumab administered within 12 weeks prior to screening. III) any B cell-depleting therapies, other than ianalumab administered within 36 weeks prior to randomization or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower). IV) Traditional Chinese medicines administered within 30 days prior to randomization
• • Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection
• • Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
• • Evidence of active tuberculosis infection
• • History of primary or secondary immunodeficiency, including a positive human immunodeficiency virus (HIV) test result at screening
• * Any one of the following abnormal laboratory values prior to randomization:
• • Platelets \< 25000/ mm\^3 (\< 25 x 10\^3/ μL)
• • Hemoglobin (Hgb) \< 8.0 g/dL (\< 5 mmol/L), or \< 7.0 g/dL (\< 4.3 mmol/L) if related to participant's SLE such as in active hemolytic anaemia
• • Absolute neutrophil count (ANC) (\< 0.8 x 10\^3/ μL)
• • Severe organ dysfunction or life-threatening disease at screening
• • Presence of severe lupus kidney disease as defined by proteinuria above 2 g/day or equivalent using spot urine protein creatinine ratio, or serum creatinine greater than 2.0 mg/dL (176.84 µmol/L), or requiring immune-suppressive induction or maintenance treatment at screening
• • Receipt of live/attenuated vaccine within a 4-week period before first dosing
• • Any uncontrolled, co-existing serious disease, which in the opinion of the investigator will place the participant at risk for participation or interfere with evaluation for SLE-related symptoms
• • Non-lupus conditions such as asthma, gout or urticaria, requiring intermittent or chronic treatment with systemic CS
• • History of malignancy of any organ system other than localized basal cell carcinoma of the skin or in situ cervical cancer
• • Pregnant or nursing (lactating) women.
• • Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while on study treatment and for 6 months after stopping of investigational drug.
• • Any surgical, medical, psychiatric or additional physical condition that may jeopardize participation in this study